Question 1

Does tirzepatide work without intensive lifestyle intervention?

Accepted Answer

SURMOUNT-1 already showed it does — that trial enrolled adults with obesity, paired tirzepatide with standard monthly lifestyle counseling rather than the structured program used in SURMOUNT-3, and reported mean weight loss of 20.9% at 15 mg over 72 weeks. SURMOUNT-3 is the complementary trial that tests whether tirzepatide adds value on top of an intensive lifestyle program. The short answer from both trials together: tirzepatide produces large weight loss whether or not it is paired with intensive behavioral support, but the absolute magnitudes are similar across designs (around 20% from baseline), suggesting the drug is the dominant driver of weight change in both settings. Lifestyle programs help with sustainability, food quality, exercise capacity, and metabolic markers, and clinical guidelines still recommend behavioral support alongside any obesity medication.

Question 2

What counted as intensive lifestyle intervention in SURMOUNT-3?

Accepted Answer

Participants worked with trained interventionists on a low-calorie diet (initially around 1,200 to 1,500 kcal per day depending on starting weight, designed to produce a 500-kcal-per-day deficit), at least 150 minutes per week of moderate-intensity physical activity ramping toward 300 minutes per week, and weekly individual or group counseling sessions during the 12-week lead-in. The behavioral curriculum drew on the same Diabetes Prevention Program and Look AHEAD methodology used in earlier obesity trials. After randomization, the lifestyle support continued throughout the 72-week treatment phase, with sessions transitioning to lower frequency over time. The intensity is roughly comparable to STEP-3's intensive behavioral therapy arm; both designs ensured that any drug effect was layered on top of an active lifestyle intervention rather than substituting for it.

Question 3

How does SURMOUNT-3 compare to STEP-3?

Accepted Answer

STEP-3 paired semaglutide 2.4 mg with intensive behavioral therapy from week zero and reported mean weight loss of 16.0% at week 68. SURMOUNT-3 ran the lifestyle phase first, then randomized only the responders to tirzepatide or placebo for 72 more weeks, and reported an additional 18.4% on tirzepatide from the randomization point — meaning total weight loss across the full 84 weeks reached roughly 26% on tirzepatide and roughly 3-4% net on placebo. The trials are not head-to-head and the populations differ slightly (SURMOUNT-3 selected for lifestyle responders, STEP-3 did not). The direct head-to-head comparison between tirzepatide and semaglutide for weight loss was answered later by SURMOUNT-5 (Aronne 2025).

Question 4

Did the 12-week lifestyle run-in skew the results?

Accepted Answer

The run-in does shape interpretation, but in a way that strengthens rather than weakens the case for tirzepatide. Because randomization only included participants who had already lost at least 5% with lifestyle alone, the population was self-selected for behavioral capability and adherence. That selection should bias the placebo arm toward better outcomes, not worse — these were the people most likely to keep losing weight without medication. Despite that, placebo participants regained 2.5% on average and only 37.8% maintained at least 80% of their initial loss, while 98.6% of tirzepatide participants did. The run-in design also answers a different question than SURMOUNT-1: whether the drug adds anything for people who already proved they can lose weight on lifestyle. The answer, in this trial, was yes — substantially.

Question 5

Should insurance require intensive lifestyle intervention before approving Zepbound?

Accepted Answer

Many commercial and Medicaid plans currently require documentation of a supervised lifestyle program (often 3 to 6 months) before approving GLP-1 medications for obesity. SURMOUNT-3 is the trial most commonly cited in appeals and policy discussions on both sides of this question. Proponents of the requirement point to the trial as evidence that lifestyle can produce 5% or more weight loss for many people on its own. Critics point to the same trial as evidence that lifestyle-only losses are not sustained — under the 37.8% maintenance rate in the placebo arm, the requirement essentially asks patients to lose weight, regain most of it, and then qualify for the medication that would have helped them keep the loss. Current AACE and Obesity Society guidelines support adding pharmacotherapy when lifestyle alone is insufficient; SURMOUNT-3 quantified what 'insufficient' looks like at the 12-month mark.

Question 6

How tolerable was tirzepatide in SURMOUNT-3 compared to other trials?

Accepted Answer

Gastrointestinal adverse events were the dominant tolerability issue and tracked the pattern seen in SURMOUNT-1 and SURMOUNT-2. Nausea (39.7% vs 14.0%), diarrhea (31.0% vs 9.2%), constipation (23.0% vs 6.8%), and vomiting (18.1% vs 1.4%) all ran several-fold higher on tirzepatide than placebo and concentrated during the 20-week dose-escalation phase. Most events were mild to moderate. Serious adverse events were similar between groups (5.9% on tirzepatide vs 4.8% on placebo), with no single SAE term affecting more than two participants in either arm. Hair loss (alopecia) was reported in 7.0% on tirzepatide versus 1.4% on placebo, consistent with the pattern of elevated hair-loss reporting that tracks the magnitude of weight loss across obesity trials rather than the drug class itself.

Endpoint	Treatment	Comparator	Difference
Coprimary: proportion achieving ≥5% additional body-weight reduction at week 72 (from randomization) Nearly nine of ten tirzepatide participants kept losing weight after the lead-in, while roughly one in six placebo participants did.	87.5% (SE 2.2)	16.5% (SE 3.0)	Odds ratio 34.6 (95% CI 19.2 to 62.6; P<0.001)
Proportion maintaining ≥80% of the weight lost during the 12-week lifestyle lead-in at week 72 Direct test of the durability question. Without drug, only about a third of participants held on to most of their lifestyle-phase loss; with tirzepatide, almost everyone did.	98.6%	37.8%	Logistic regression favored tirzepatide; P<0.001
Proportion achieving ≥10% additional body-weight reduction from randomization to week 72	88.0%	4.8%	P<0.001
Proportion achieving ≥15% additional body-weight reduction from randomization to week 72	73.9%	2.1%	P<0.001
Proportion achieving ≥20% additional body-weight reduction from randomization to week 72 More than half of tirzepatide participants lost an additional ≥20% on top of what they had already lost during the lifestyle lead-in.	54.9%	1.0%	P<0.001
Change in waist circumference from randomization to week 72 (cm)	-16.8 cm (SE 0.56)	+1.1 cm (SE 0.58)	Estimated treatment difference roughly -17.9 cm
Change in systolic blood pressure from randomization to week 72 (mmHg) Placebo participants' systolic blood pressure rose alongside their weight regain, widening the between-group gap.	-5.8 mmHg (SE 0.73)	+4.4 mmHg (SE 0.76)	Estimated treatment difference roughly -10.2 mmHg
Percent change in triglycerides from randomization to week 72	-25.8% (SE 1.61)	+3.0% (SE 2.34)	Estimated treatment difference roughly -29 percentage points
Percent change in total cholesterol from randomization to week 72	-3.0% (SE 0.97)	+5.2% (SE 1.11)	Estimated treatment difference roughly -8 percentage points
Change in HbA1c from randomization to week 72 (%) Participants were non-diabetic at entry; the HbA1c drop reflects shifts within the normoglycemic/prediabetic range.	-0.46% (SE 0.020)	+0.01% (SE 0.022)	Estimated treatment difference roughly -0.47 percentage points
Change in fasting plasma glucose from randomization to week 72 (mg/dL)	-8.8 mg/dL (SE 0.82)	+2.4 mg/dL (SE 0.86)	Estimated treatment difference roughly -11.2 mg/dL

Event	Treatment rate	Comparator rate
Nausea Most common AE on tirzepatide; typically mild-to-moderate and concentrated during the 20-week dose-escalation phase.	39.7% (114/287)	14.0% (41/292)
Diarrhea	31.0% (89/287)	9.2% (27/292)
Constipation	23.0% (66/287)	6.8% (20/292)
Vomiting Largest relative excess of any GI event vs placebo.	18.1% (52/287)	1.4% (4/292)
Injection-site reaction	11.1% (32/287)	1.0% (3/292)
Abdominal pain	10.5% (30/287)	2.4% (7/292)
Dyspepsia	9.4% (27/287)	3.1% (9/292)
Decreased appetite	9.4% (27/287)	4.1% (12/292)
Headache	9.4% (27/287)	7.5% (22/292)
Alopecia (hair loss) Hair loss tends to track the magnitude of weight loss rather than the drug itself; rates were similarly elevated in SURMOUNT-1.	7.0% (20/287)	1.4% (4/292)
Serious adverse events (any) No single SAE term affected more than two tirzepatide participants. One death occurred in each arm; neither was assessed as related to study drug.	5.9% (17/287)	4.8% (14/292)

SURMOUNT-3 deep dive: tirzepatide after intensive lifestyle intervention

Primary endpoint

Secondary endpoints

Adverse events

Clinical significance

Frequently Asked Questions

References

Related trial deep-dives